Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of avacopan in C3 glomerulopathy
NL-OMON48649Phase 2Active, not recruiting
- Sponsor
- ChemoCentryx
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Complement 3 glomerulopathy (C3G) comparing Avacopan with Placebo then avacopan (2 arms). Primary endpoint: Percent change from baseline to Week 26 in C3G Histologic Index for disease activity. Started Apr 2018; status: active, not recruiting.
02
Drugs
avacopan
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on NL-OMON48649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48649.